Molecular docking study of catecholamines and [4-(propan-2-yl) phenyl]carbamic acid with tyrosine hydroxylase

CNS and Neurological Disorders - Drug Targets

Volumn 11, Issue 4, 2012, Pages 463-468

  Parveen, Zahida ^a   Nawaz, Muhammad Sulaman ^b   Shakil, Shazi ^c   Greig, Nigel H ^d   Kamal, Mohammad A ^c  

^a QUAID I AZAM UNIVERSITY   (Pakistan)

^b Department of Biosciences   (Pakistan)

^c KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^d NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Catecholamine; Docking study; Novel inhibitor; Parkinson's disease; Tyrosine hydroxylase

Indexed keywords

ADRENALIN; AMINO ACID; CARBAMIC ACID DERIVATIVE; NORADRENALIN; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; [4 (PROPAN 2 YL)PHENYL]CARBAMIC ACID;

ARTICLE; CATECHOLAMINE RELEASE; DRUG BINDING; DRUG STRUCTURE; DRUG TARGETING; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR DOCKING; PARKINSON DISEASE; PHEOCHROMOCYTOMA;

EID: 84862573677     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/187152712800792884     Document Type: Article

References (18)

1. Nussbaum, R.L.; Ellis, C.E. Alzheimer's disease and Parkinson's disease. N. Engl. J. Med., 2003, 348(14), 1356-1364.
2. Booij, J.; Bergmans, P.; Winogrodzka, A.; Speelman, J.D.; Wolters, E.C. Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease. Synapse, 2001, 39, 101-108.
3. Miller, R.M.; Federoff, H.J. Altered gene expression profiles reveal similarities and differences between Parkinson disease and model systems. Neuroscientist, 2005, 11(6), 539-549.
4. Schapira, A.H.V. Treatment options in the modern management of Parkinson disease. Arch. Neurol., 2007, 64(8), 1083-1088.
5. Kroemer, R.T. Molecular modelling probes: docking and scoring. Biochem. Soc. Trans., 2003, 31(Pt 5), 980-984.
6. Walther, M.M.; Keiser, H.R.; Linehan, W.M. Pheochromocytoma: evaluation, diagnosis, and treatment. World J. Urol., 1999, 17(1), 35-39.
7. Harari, A.; Inabnet, W.B., 3rd. Malignant pheochromocytoma: a review. Am. J. Surg., 2011, 201(5), 700-708.
8. Morris, G.M.; Huey, R.; Lindstrom, W.; Sanner, M.F.; Belew, R.K.; Goodsell, D.S.; Olson, A.J. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem., 2009, 30(16), 2785-2791.
9. Pettersen, E.F.; Goddard, T.D.; Huang, C.C.; Couch, G.S.; Greenblatt, D.M.; Meng, E.C.; Ferrin, T.E. UCSF Chimera-a visualization system for exploratory research and analysis. J. Comput. Chem., 2004, 25(13), 1605-1612.
10. Daubner, S.C.; Le, T.; Wang, S. Tyrosine hydroxylase and regulation of dopamine synthesis. Arch. Biochem. Biophys., 2011, 508(1), 1-12.
11. Goodwill, K.E.; Sabatier, C.; Marks, C.; Raag, R.; Fitzpatrick, P.F.; Stevens, R.C. Crystal structure of tyrosine hydroxylase at 2.3 Å and its implications for inherited neurodegenerative diseases. Nat. Struct. Biol., 1997, 4, 578-585.
12. Michalakis, K.; Ilias, I. Medical management of adrenal disease: anarrative review. Endocr. Regul., 2009, 43(3), 127-135.
13. van der Horst-Schrivers, A.N.A.; Kerstens, M.N.; Wolffenbuttel, B.H.R. Preoperative pharmacological management of phaeochromocytoma. Nether. J. Med., 2006, 64, 290-295.
14. Booij, L; Van der Does, A.J.; Riedel, W.J. Monoamine depletion in psychiatric and healthy populations: review. Mol. Psychiatry, 2003, 8(12), 951-973.
15. Brodie, H.K.; Murphy, D.L.; Goodwin, F.K.; Bunney, W.E. Catecholamines and mania: the effect of alpha-methyl-paratyrosine on manic behavior and catecholamine metabolism. Clin. Pharmacol. Ther., 1971, 12, 218-224.
16. Bunney, W.E.; Brodie, H.K.H.; Murphy, D.L.; Goodwin, F.K. Studies of alpha-methyl-para-tyrosine, L-dopa, and L-tryptophan in depression and mania. Am. J. Psychiatry, 1971, 127, 872-881.
17. Ono, M.; Okamoto, M.; Kawabe, N.; Umezawa, H.; Takeuchi, T. Oudenone, a novel tyrosine hydroxylase inhibitor from microbial origin. J. Am. Chem. Soc., 1971, 93(5), 1285-1286.
18. Ayukawa, S.; Takeuchi, T.; Sezaki, M.; Hara, T.; Umezawa, H. Inhibition of tyrosine hydroxylase by aquayamycin. J. Antibiot., 1968, 21(5), 350-353.